Longevity Medical Institute launches intranasal neurological therapy platform

Longevity Medical Institute in San José del Cabo, Mexico, has launched a regenerative neurology program built around a new intranasal delivery platform for selected neurological conditions. The institute says the approach offers a less invasive alternative to intrathecal treatment and expands options for physician-guided regenerative care.

Why it matters: - Longevity Medical Institute is adding a non-invasive route for delivering regenerative therapies to the brain, which could broaden options for patients with selected neurological disorders. - The new platform is designed as an alternative to intrathecal administration, which requires a lumbar puncture. - The institute is positioning the launch as part of a broader push in regenerative neurology, where delivery method can shape who can be treated and how comfortably.

What happened: - Longevity Medical Institute announced the launch of its Regenerative Neurological Therapy Program on July 23, 2026. - The program includes an intranasal delivery platform intended to transport regenerative therapies through the nasal cavity toward the brain. - The institute said the platform expands its neurological program by offering a less invasive option for selected conditions. - The institute is based in San José del Cabo, Baja California Sur, Mexico.

The details: - The platform targets the upper nasal cavity near the olfactory region, rather than the lower nasal passages reached by conventional sprays. - The delivery system uses an electronically controlled nebulizer that produces microscopic aerosol droplets over several minutes. - The controlled delivery is intended to increase contact time in the olfactory region, reduce medication loss into the throat, and improve consistency. - Longevity Medical Institute uses the platform only for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes, and selected therapeutic peptides. - Treatment recommendations come from a multidisciplinary physician team after neurological evaluation that may include advanced imaging, laboratory testing, neurological examination, and review of medical history. - The institute also offers intravenous regenerative therapies, intrathecal administration in its licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging, and multidisciplinary physician care. - For more information about the program, visit the institute's announcement.

Between the lines: - The launch reflects a bet that nose-to-brain delivery can help overcome one of neurology's biggest constraints: getting therapies past the blood-brain barrier. - Dr. Kirk Sanford, founder and CEO, said the new platform expands the institute's ability to personalize treatment and lets physicians choose between intrathecal and intranasal administration based on diagnosis, clinical findings, and treatment goals. - Sanford also said the institute aims to combine scientific evidence with advanced diagnostics and physician-guided planning. - The institute cites published human research reporting encouraging safety findings for MSC-based therapies, but the evidence remains early and condition-specific. - The company also notes that larger randomized clinical trials are still needed to define which patients may benefit most and how durable responses may be.

What's next: - The institute says future treatment decisions will continue to rely on physician evaluation, published scientific evidence, patient-specific factors, and clinical judgment. - Broader adoption will likely depend on additional clinical research that clarifies effectiveness, durability, and patient selection. - Longevity Medical Institute is framing regenerative neurological therapy as a fast-growing area of translational medicine, suggesting more development may follow.

The bottom line: - Longevity Medical Institute is trying to make brain-targeted regenerative care less invasive by adding an intranasal option to its neurological treatment toolkit.